| 1 |
34863085 | Useful predictors of progression-free survival for Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer who received upfront abiraterone acetate. | 2022 Mar |
1 |
| 2 |
34970742 | Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study. | 2022 Mar |
2 |
| 3 |
35129730 | P2Y1 agonist HIC in combination with androgen receptor inhibitor abiraterone acetate impairs cell growth of prostate cancer. | 2022 Apr |
3 |
| 4 |
35201849 | A Case of Prostate Cancer Harboring Androgen Receptor T878A Progesterone-Responsive Mutant Emerging After Abiraterone Acetate Treatment Responding to Darolutamide. | 2022 Feb |
1 |
| 5 |
35229000 | Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer. | 2022 Mar |
1 |
| 6 |
35352309 | Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents. | 2022 Jun |
1 |
| 7 |
35513478 | Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer. | 2022 May 5 |
2 |
| 8 |
31601523 | Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. | 2021 Aug |
1 |
| 9 |
33140306 | Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer. | 2021 Mar |
1 |
| 10 |
33981146 | Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From "All-Comers" to "Personalized" Approach. | 2021 |
1 |
| 11 |
34041015 | Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor. | 2021 |
1 |
| 12 |
34128827 | Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer. | 2021 Jul 15 |
1 |
| 13 |
34513709 | Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. | 2021 |
1 |
| 14 |
31412017 | Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. | 2020 Feb |
2 |
| 15 |
32944530 | The efficacy and safety of abiraterone acetate in patients with high-risk prostate cancer: a meta-analysis based on six randomized control trials. | 2020 Aug |
2 |
| 16 |
30352905 | Enhancing Abiraterone Acetate Efficacy in Androgen Receptor-positive Triple-negative Breast Cancer: Chk1 as a Potential Target. | 2019 Jan 15 |
2 |
| 17 |
30770950 | Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines. | 2019 Jun |
11 |
| 18 |
31239713 | Androgen upregulates the palmitoylation of eIF3L in human prostate LNCaP cells. | 2019 |
1 |
| 19 |
32923850 | Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. | 2019 |
1 |
| 20 |
28844372 | Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. | 2018 Jul |
1 |
| 21 |
29266182 | Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC). | 2018 Mar 15 |
2 |
| 22 |
29398263 | Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer. | 2018 Jun |
1 |
| 23 |
29460922 | Cellular plasticity and the neuroendocrine phenotype in prostate cancer. | 2018 May |
2 |
| 24 |
29688882 | Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces. | 2018 Oct |
1 |
| 25 |
29856649 | Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer. | 2018 Jun |
2 |
| 26 |
29988102 | Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. | 2018 Nov |
1 |
| 27 |
30101644 | Apalutamide for the treatment of prostate cancer. | 2018 Sep |
1 |
| 28 |
28490267 | Darolutamide (ODM-201) for the treatment of prostate cancer. | 2017 Jun |
3 |
| 29 |
26779767 | Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer. | 2016 May |
2 |
| 30 |
26827690 | AR-V7 and prostate cancer: The watershed for treatment selection? | 2016 Feb |
1 |
| 31 |
27052658 | A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). | 2016 May |
1 |
| 32 |
27062039 | Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. | 2016 May |
1 |
| 33 |
27106175 | Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. | 2016 Nov |
1 |
| 34 |
27502737 | Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer. | 2016 Dec |
1 |
| 35 |
27628492 | Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. | 2016 Dec |
2 |
| 36 |
28058266 | Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis. | 2016 |
1 |
| 37 |
25236176 | Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies. | 2015 Feb 1 |
1 |
| 38 |
25534660 | Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. | 2015 Mar |
1 |
| 39 |
24053777 | The transcriptional programme of the androgen receptor (AR) in prostate cancer. | 2014 Mar |
1 |
| 40 |
24390422 | Novel drugs targeting the androgen receptor pathway in prostate cancer. | 2014 Sep |
1 |
| 41 |
24840076 | Evolution of androgen receptor targeted therapy for advanced prostate cancer. | 2014 Jun |
1 |
| 42 |
24859991 | Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. | 2014 Aug |
1 |
| 43 |
25047002 | Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate. | 2014 Sep |
1 |
| 44 |
25341420 | Androgen metabolic pathway involved in current and emerging treatment for men with castration resistant prostate cancer: intraprostatic androgens as therapeutic targets and endocrinological biomarkers. | 2014 |
1 |
| 45 |
23199349 | Abiraterone acetate for the treatment of prostate cancer. | 2013 Jan |
1 |
| 46 |
23576708 | Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). | 2013 Jul |
2 |
| 47 |
23752182 | Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. | 2013 Dec 5 |
1 |
| 48 |
23793763 | Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets. | 2013 Jun |
1 |
| 49 |
21372223 | New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. | 2011 Apr 1 |
2 |
| 50 |
21604955 | Broadening horizons in medical management of prostate cancer. | 2011 Jun |
2 |